Protein-based nanoparticles as a drug delivery system: chances, risks, perspectives

https://doi.org/10.1016/S1773-2247(10)50056-XGet rights and content

Abstract

This review aims to provide a broad overview of the development of drug delivery nanoparticulate systems, their classification by basic material, preparation method and administration route while focusing on recent trends in the field of protein-based nanoparticles. Literature on drug delivery by nanotechnology was reviewed in the light of previous and ongoing research. Potentials and challenges including regulatory issues are discussed in the context of possible applications of the miscellaneous nanoparticle devices. Over the past years homogeneous and clearly size-defined nanoparticles have been successfully designed from a large variety of starting materials. These nanoparticles offered diverse targeting or imaging properties in order to either enhance pharmacodynamic efficiency or reduce side effects of the delivered drug substance or to monitor the system’s fate in vivo. The latter is considered especially crucial when it comes to finally guiding nanoparticulate formulations through the clinical phase and its use for the patient’s benefit in the end. If the clinical requirements can be met, the main promises of the new nanoparticulate formulations and associated new routes of drug delivery can be met (a) to enable new types of medicines to be carried to previously inaccessible sites within the body or (b) to reduce risks in delivering already established drugs.

References (0)

Cited by (26)

  • Updated but not outdated “Gliadin”: A plant protein in advanced pharmaceutical nanotechnologies

    2020, International Journal of Pharmaceutics
    Citation Excerpt :

    The amphiphilic nature of proteins, being biodegradable and metabolizable, offer an infinitude of components reachable to alterations to adapt drug-binding, imaging, or targeting (Weber et al., 2000). Compared with synthetic proteins, they are non-toxic and no substance-related toxicity was reported (Fuchs and Coester, 2010). The large molecular size of proteins, unlike those of traditional pharmaceutical carriers, together with having secondary and triennial structure, makes them vulnerable to physical and chemical degeneration (Gupta and Sharma, 2009).

  • The effects of radiation and experimental conditions over papain nanoparticle formation: Towards a new generation synthesis

    2020, Radiation Physics and Chemistry
    Citation Excerpt :

    In the last few decades’ nanomaterials were studied for different kinds of applications mainly regarding pharmaceutical and biomedical areas as drug carriers and/or alternative options with less or null collateral effects (Lohcharoenkal et al., 2014). Protein belongs to an important group of materials recently employed at nanoscale to provide essential properties, such as ideal particle size, high biocompatibility, low toxicity (Tarhini et al., 2017) and cost among other features (Fuchs and Coester, 2010). Within this context products and techniques have been recently developed, e.g. albumin bound paclitaxel, commercially known as Abraxane® – a chemotherapeutic medicine of highlighted interest for breast cancer (Grandishar, 2006); crosslinked enzyme aggregates (CLAE) with application in biocatalyst (Sheldon, 2011); papain-based products for biomedical applications (Singh and Singh, 2012) and many others.

  • Zein-casein-lysine multicomposite nanoparticles are effective in modulate the intestinal permeability of ferulic acid

    2019, International Journal of Biological Macromolecules
    Citation Excerpt :

    Biodegradable nanoparticles have been widely applied to circumvent biopharmaceutical and pharmacokinetic drawbacks of drugs, allowing their application for several routes, including the oral administration. Protein-based nanoparticles have been gaining pronounced interest in recent years due to their low toxicity, biodegradability, and ability to attachment of hydrophobic and hydrophilic drugs and ligands at their surface [12,13]. Zein is a protein of the prolamin class found in corn [14].

  • Cereal protein-based nanoparticles as agents stabilizing air–water and oil–water interfaces in food systems

    2019, Current Opinion in Food Science
    Citation Excerpt :

    Indeed, cereal prolamins such as maize zeins (MZ) and wheat gliadins (WG) have been widely used as material for producing biocompatible carrier nanoparticles (NPs). Studies in this field are abundant, have been excellently reviewed on several occasions [8–11] and, therefore, will not be the focus of the present review. However, cereal protein-based NPs may also be used to provide structure and texture in food systems.

  • A review on pH and temperature responsive gels and other less explored drug delivery systems

    2018, Journal of Drug Delivery Science and Technology
    Citation Excerpt :

    Although polymeric nanoparticles have proven to be effective drug delivery systems, they possess disadvantages for applications with biological environments which include use of toxic solvents in formulation process, polymer degradation, drug leakage, and polymer cytotoxicity [115]. Interestingly, protein nanoparticles have an advantage in being effective in the targeted delivery of biologicals such as antibodies, vaccines, enzymes, hormones [116] or other forms of treatment such as gene therapy, chemotherapy, and viral vectors [117]. However, protein selection, for bioactivity is determined on the three-dimensional conformation of the protein itself [116].

  • Layer-by-layer polyelectrolyte coating of alginate microgels for sustained release of sodium benzoate and zosteric acid

    2018, Journal of Drug Delivery Science and Technology
    Citation Excerpt :

    In our study, we created LbL deposited polyelectrolyte bilayers on alginate microgels (LbL-Alg-Ms) as drug carriers. Alginate, a linear anionic polysaccharide, has been widely investigated as a carrier material for drug delivery [38–40]. The LbL deposited polyelectrolyte bilayers were hypothesized to serve as a diffusion barrier that would significantly retard the release of very small hydrophilic drugs (Mw < 250 g/mol, solubility in water > 33 mg/mL) by increasing the diffusion path and potentially introducing molecular interactions, such as electrostatic interactions and hydrogen-bonding, between drug molecules and the bilayers.

View all citing articles on Scopus
View full text